Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2025
Reporting Period: Event date April 24, 2025; Anticipated closing on or about April 28, 2025.
The Company, an emerging growth company, commenced a best efforts public offering of common stock and warrants. The securities were registered under a Form S-1 declared effective on April 24, 2025.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Shares Offered | 3,133,333 shares of Common Stock |
| Warrants Issued | 3,133,333 Series B-1 Warrants and 3,133,333 Series B-2 Warrants |
| Offering Price | $0.75 per share (including accompanying warrants) |
| Warrant Exercise Price | $0.85 per share |
| Expected Net Proceeds | Approximately $1.9 million |
| Placement Agent Fee | 7.0% of gross proceeds |
| Legal Expense Cap | $80,000 (reimbursable) |
Use of Proceeds: Enrollment of patients in the INVINCIBLE-4 Study, treatment of patients in the INVINCIBLE-3 Study, and working capital/general corporate purposes.
Material Changes and Agreements
- Securities Purchase Agreement: Entered into with institutional investors on April 24, 2025.
- Lock-up Restrictions: The Company agreed to restrictions on issuing Common Stock or equivalents for 30 days post-closing, with exceptions for up to $5.0 million in registered offerings to existing shareholders/investors at or above the offering price.
- Variable Rate Transaction Ban: Prohibited for 60 days post-closing, subject to exceptions.
- Warrant Ownership Limits: Holders cannot exercise warrants to own more than 4.99% (or 9.99% with notice) of outstanding Common Stock immediately after exercise.
- Warrant Expiration: Series B-1 expires in 5 years; Series B-2 expires in 18 months.
Outlook, Risks, and Management Commentary
Outlook: The Company anticipates closing the offering on or about April 28, 2025, subject to customary closing conditions. The capital raise is specifically targeted to advance clinical trial enrollment (INVINCIBLE-4) and patient treatment (INVINCIBLE-3).
Risks and Contingencies:
- The offering is a "best efforts" transaction, meaning the full amount of shares may not be sold.
- Closing is subject to satisfaction of customary conditions.
- Future dilution is capped by the 4.99%/9.99% beneficial ownership limits on warrant exercises.
Unusual Items: The filing does not disclose unusual items beyond the standard terms of the equity offering and placement agent agreements.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds raised (expected closing ~April 28, 2025).
- Confirm the exact number of shares and warrants sold if the offering is not fully subscribed.
- Review the Pricing Press Release (Exhibit 99.1) for specific investor details and final pricing confirmation.
- Monitor the Company's cash runway extension relative to the $1.9 million net proceeds target.
- Check for any subsequent filings regarding the exercise of warrants or issuance of additional shares under the 30-day lock-up exceptions.